anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a preparation method of a traditional Chinese medicinal peach kernel solution for treating constipation. The traditional Chinese medicinal peach kernel solution consists of the following ingredients: 6-15 parts of (dried) peach kernels, 8-18 parts of radix codonopsis, 8-16 parts of lucid ganoderma, 4-12 parts of linseed, 6-16 parts of radix angelicae sinensis, 5-30 parts of radix salviae miltiorrhizae, 3-15 parts of fructus crataegi, 6-18 parts of red yeast rice, 6-12 parts of radix asteris and 5-14 parts of songaria cynomorium herb. The concentration of 95% edible ethanol leaching solution is 5-30% (in percentage by volume), and the traditional Chinese medicine, namely the peach kernel, is leached for 5-30 days. The preparation method of the traditional Chinese medicinal peach kernel solution for treating the constipation provided by the invention is simple and safe, free from toxicity and pollution and low in cost. A solution of omega 3 generated from [alpha]-linolenic acid through an in-vivo biochemical reaction is used for cleaning blood and blood vessel wastes (toxins) and solutions of the fructus crataegi, the red yeast rice and the like are used for promoting complete nutrition digestion and absorption of intestines and stomach, so as to meet nutrition (energy) demands of body metabolism (such as nourishing blood) and physiological activities. An immune system having a medical function is assisted by clean blood and sufficient nutrition (energy) as well as constipation treating drugs, so as to relax bowels for constipation due to intestinal dryness as well as to boost body immunity and promote body self-cure rate.
Adolescents, boys and girls, aged 16-19 participated in beta testing this PlaySmart storyline where the player navigates supporting their partner struggling with opioid misuse. This storyline includes information about treatment and recovery resources for opioid misuse \& Opioid Use Disorder.
A drug delivery system includes a first computer device, a display device, a motion sensing device, and a second computer device. The display device and the motion sensing device are connected to the first computer device, which is coupled to the second computer device. The first computer device is configured to execute commands relating with an operational interface. The display device is configured to display the operational interface and a drug list on the operational interface. The motion sensing device has an image capture device configured to capture image data and depth data from a motion of an operator to simulate an input carried out by the operator. Based on the input carried out by the operator, the first computer device determines which drugs are selected. The second computer receives a list of the selected drugs transmitted from the first computer. A drug delivery system is also provided.
Each participant was assigned to a highly skilled dietician. The dietician implemented an individualized daily dietary regimen according to the Mediterranean diet produced by the clinical decision support system (CDSS) software. The CDSS was utilized to calculate all necessary components for the synthesis of the dietary plan, which was renewed every 15 days. Participants of the Intervention group obtained unique login credentials for the CDSS and received instruction on its operation from the designated dietitians. They were directed to access their CDSS account remotely on a weekly basis in order to monitor their nutritional status (body weight and healthy eating) and to complete a three-day dietary journal; this information was automatically accessible to the dietitians. Telephone interviews were conducted every other week in order to supplement the nutritional and lifestyle consultations. In addition, unanticipated phone calls requesting 24-hour dietary recalls were received.
NEW MATERIAL:A compound shown by formula I (R1 and R2 are H or lower alkyl; R3 and R4 are H, lower alkoxy, amino or halogen; R5 and R6 are lower alkyl or R5 and R6 together with N are bonded to form 1-pyrrolidinyl or piperidino) and an acid addition salt thereof. EXAMPLE:N-{ 4-(2-(Dimethylamino) ethoxy]benzyl }-2-methoxy-5-sulfamoylbenza mide. USE:A reactivator for motion of digestive tube having excellent activating action on digestive tube, useful for improving various indefinite complaint symptoms followed by reduction in motion function of gastrointestinal tract. PREPARATION:A carboxylic acid shown by formula II is converted into a reactive derivative thereof (acid chloride, acid anhydride or mixed acid anhy dride) and reacted with an amine shown by formula III including a novel com pound in the presence or absence of a base (e.g. pyridine or picoline) in an inert organic solvent (e.g. ether or benzene) to give a compound shown by formula I.
Adverse systemic reactions usually occur within minutes and consist primarily of allergic symptoms such as: generalized skin erythema, urticaria, pruritus, angioedema, rhinitis, wheezing, laryngeal edema, itching of nose and throat, breathlessness, dyspnea, coughing, hypotension and marked perspiration. Less commonly, nausea, emesis, abdominal cramps, diarrhea and uterine contractions may occur. Severe reactions may cause anaphylaxis or shock and loss of consciousness. In rare instances this may result in death. 

The treatment of systemic allergic reactions is dependent upon the system complex. Antihistamines may offer relief of recurrent urticaria, associated skin reactions and gastrointestinal symptoms. Corticosteroids may provide benefit if symptoms are prolonged or recurrent. (See Overdosage)

Local Reactions consisting of erythema, itching, swelling tenderness and sometimes pain may occur at the injection site. These reactions may appear within a few minutes to hours and persist for several days. Local cold applications and oral antihistamines may be effective treatment. For marked and prolonged local reactions the use of antihistamines or anti-inflammatory medications may be indicated.

Serious adverse reactions should be reported to Nelco Laboratories immediately and a report can be filed to: MedWatch, The FDA Medical Product Problem Reporting Program, at 5600 Fishers Lane, Rockville, MD 20852-9787, call 1-800-FDA-1088.
Masses for filling dental cavities, which masses harden in the mouth, comprise a solution in a physiologically compatible, water-soluble or water-miscible solvent, of a synthetic resin which solution hardens in water and into which solution zinc oxide and calcium sulphate have been incorporated in an amount sufficient to give a kneadable, firm, stable and paste-like mass. The synthetic resin is defined as a polymethacrylate, polyvinyl acetate or polyvinyl chloride.  The preferred resin is polymethyl methacrylate and the preferred solvent is ethyl lactate.  The zinc oxide and calcium sulphate are preferably used in approximately equal parts by weight.  Other solvents are glycerol triacetate, acetic acid esters of other polyhydric alcohols, e.g. ethylene glycol and butylene glycol, and other esters of lactic acid.
BACKGROUND: Chronic lymphoid leukemia (CLL) is a hematological disorder characterized by the clonal expansion of small mature lymphocytes that accumulate in the blood and bone marrow. CLL can arise from B-, T-, or natural killer cell clones. The cytological evaluation of blood smears is often the simplest and least invasive method for diagnosing lymphoid leukemia. Immunophenotyping is used to further subclassify the type of lymphoid leukemia.
CASE PRESENTATION: A 15-year-old, 4.4-kg spayed female Shih Tzu was presented to the veterinary medical teaching hospital of Kangwon National University. Despite having a normal appetite and activity level, cervical and inguinal lymph node enlargement was noted on physical examination. Complete blood count revealed severe leukocytosis, severe lymphocytosis, and monocytosis. Splenomegaly, hepatomegaly, and lymph node enlargement were detected on radiographic and ultrasonographic examination. Immunophenotyping was performed using peripheral blood mononuclear cells (PBMCs). The majority of lymphocytes exhibited the following profiles: CD3-CD79a- (97.5%), CD4-CD8- (98.6%), CD21-CD79a- (98.4%), CD34- (0.1%), CD45+ (99.6%), major histocompatibility complex class II+ (99.5%), and CD14- (0.5%). Based on the immunophenotyping results, possible differentials considered included the following: the majority of lymphocytes may be natural killer (NK) cell clones, plasma cell clones, or show aberrant expression or loss of CD21 marker due to the neoplastic nature of the cells. Further flow cytometry was performed using antibodies against CD3, CD5, CD94, and granzyme B. The combined results indicated that the predominant lymphocyte subset in the PBMCs was CD3-CD5-CD21-CD94-granzyme B-. To confirm monoclonality and exclude the aberrant loss of CD markers, a polymerase chain reaction for antigen receptor rearrangement (PARR) assay was conducted. The PARR assay, using DNA from blood and lymph node samples, showed B-cell monoclonality. Immunocytochemistry using PBMCs showed that the plasma cell marker Multiple Myeloma Oncogene 1 (MUM1) was not expressed. Therefore, the diagnosis was confirmed to be B-cell CLL.
CONCLUSION: Immunophenotyping can help subclassify the type of lymphoid leukemia; however, as tumor cells can show aberrant expression or loss of the CD21 marker, combining immunophenotyping with the PARR assay could yield a more accurate diagnosis.
Cohort 1 will receive 15mg of SPQ every day for 5 days. Cohort 2 will receive 22.5 mg of SPQ every day for five days.
The invention discloses traditional Chinese medicine fumigation-washing agent for treating peripheral nerve entrapment. In the traditional Chinese medicine, the peripheral nerve entrapment is categorized as infantile paralysis and arthralgia, and caused by weakness of the body, cold-damp blockage of channel and qi and blood blockage due to cold and dampness and pathological product sputum. In order to solve the problems, the traditional Chinese medicines, which have the effects of warming channels to dispel cold, dredging grains and promoting the flow of qi and blood, are selected and prepared into a fumigation-washing agent for carrying out fumigation-washing to diseased region, wherein the medicines are as follows: fragile blueberry root, lycopodium calvatum, tonkin pepper herb, starjasmine stem, coralbean bark, raw salt, common calanthe herb, delavay violet root, henry clematis root of leaf, Yunnan begonia herb and liquorice. Among the clinical tests of 138 patients of our preparation department, 120 patients are recovered by taking the medicine, 6 patients are almost recovered by taking the medicine, the medicine is valid to 8 patients and invalid to 4 patients after one treatment course; and among 18 patients who are not completely recovered, 14 patients are recovered by taking the medicine, and the medicine is valid to two patients and invalid to two patients after the second treatment course. According to the further test, the 4 patients who are incompletely recovered have lumbar intervertebral disc herniation. According to the follow-up visits to the 34 recovered patients during the whole year, the peripheral nerve entrapment relapses on no patient.
The invention belongs to the technical field of cell biology, and discloses a compound inhibitor for effectively inhibiting the antioxidant bioactivity of cells. The compound inhibitor comprises the following components: l-buthionine-sulfoxide imine (1.5mM), 3-amino-1, 2, 4-triazole (10mM), sodium diethyldithiocarbamate trihydrate (5mM), mercaptosuccinic acid (5mM), carmustine (5 μ M). The preparation method of the compound inhibitor comprises the following steps: calculating the weight of each component according to the working concentration, weighing, fully mixing, dissolving in the required culture medium, and performing suction filtration through a microporous filter membrane. The compound inhibitor can obviously reduce the induction effect of the antioxidant on the total antioxidant capacity of cells, and obviously weakens the inhibition effect of the antioxidant on the formation of Reactive Oxygen Species (ROS). The inhibitor is added alone, and has no obvious toxic and side effects on cells. Meanwhile, the compound inhibitor is water-soluble and can be directly dissolved in a cell culture solution.
The invention relates to a dose control system configured for an injectable drug delivery device. The device comprises a disk-shaped diametral single-dipole magnet ( 9 ) attachable to a rotatable dose wheel, a housing removably attachable to the proximal extremity of the drug delivery body and comprising at least a first and a second magnetic field measurement means ( 8 ). An integrated control unit ( 2 ) is connected to the magnetic field measurement means and is configured to process information received therefrom. The magnetic field measurement means are located in the housing in a displaced axial relationship relative to the longitudinal axis of the drug delivery body and the magnet. The magnet is configured to co-rotate with the dose setting wheel and the integrated control unit is configured to provide a normalized vector with regard to the displaced axial relationship of the magnetic field measurement means, said normalized vector being derived from the measured magnetic field generated by the rotation of the magnet and measured by the magnetic field measurement means. A dose setting is calculated from said normalized vector.
BACKGROUND: The urgency of maintaining a safe and adequate blood supply is increasing. One approach to ensure a sufficient supply is to limit the outdating frequency of blood components. Pathogen inactivation technology was developed primarily to increase safety by preventing transmission of infectious diseases. The Intercept Blood System for pathogen reduction of red blood cells (RBC) has additional benefits such as inactivation of leucocytes and removal of plasma and storage debris through centrifugation. Irradiation and automated washing are detrimental to the RBC membrane and often implicate shortened shelf-life. We aimed to assess whether pathogen inactivation can replace RBC irradiation and washing to avoid shelf-life reduction.
MATERIALS AND METHODS: RBC concentrates (No.=48) were pooled-and-split into four study arms, which underwent pathogen inactivation treatment, irradiation, automated washing or no treatment (reference). RBC quality was evaluated during 42 days by assessment of storage lesion. Washing efficacy was defined by IgA and albumin reduction.
RESULTS: Pathogen reduced RBCs had similar membrane preservation to reference RBCs (hemolysis, microvesicles and extracellular potassium ions), whereas the RBCs were negatively impacted by irradiation or automated washing. ATP increased substantially post-pathogen inactivation, while 2,3-DPG decreased. Pathogen inactivation considerably reduced albumin and IgA, though slightly less efficiently than automated washing.
DISCUSSION: RBCs exhibit superior membrane preservation after pathogen inactivation treatment, compared to both irradiation and automated washing. This suggests that replacement is possible, even though the plasma reduction protocol could be further optimised.Replacement of irradiated and washed RBC concentrates with pathogen reduced RBC concentrates storable up to 42 days would be advantageous for both the blood supply and patient safety.
PURPOSE:To produce titled glass having no internal defects with good spread of melt to a casting mold by subjecting a glassy casting prepd. by adding an Li2O component to the compsn of a ternay component system of CaO-Al2O3-P2O5 to multiple stages of crystallization treatments while heating up said casting. CONSTITUTION:The Li compd. of the atm. corresponding to 0.01-5pts.wt. in terms of Li2O by 100pts.wt. in total of 10-60wt% CaO, 5-25wt% Al2O3 and 25-85wt% P2O5 is added to the raw material mixture of CaO-Al2O3-P2O5 composed of the respective above-mentioned compsn. Such mixture is melted and cast to produce the glassy casting. The glassy casting is heated and is first crystallized at the temp. slightly higher than the softening point of the glass, then the temp. is slightly raised and the casting is again subjected to the crystallization treatment. The crystallization treatment is executed while raising the temp. in the above-mentioned manner and finally the casting is treated at the crystallization temp. of calcium phosphate. The spread of the melt to the melt to the casing mold is improved by the addition of Li2O to the casting and the titled glass having no defects such as pores is obtd. by multiple stages of the crystallization treatments. This glass is adequately usable as a dental material, artificial bone material, etc.
BACKGROUND: Early chest tube removal should be considered to enhance recovery after surgery. The current study aimed to provide a predictive algorithm for air leak episodes (ALE) and to create a knowledge base for early chest tube removal.
METHODS: This retrospective study enrolled patients who underwent thoracoscopic anatomical pulmonary resections in our unit. We defined ALE as any airflow ≥ 10 mL/min recorded in the follow-up charts based on the digital thoracic drainage device. Multivariate regression analysis was used to control for preoperative and intraoperative confounding factors. The ALE prediction algorithm was constructed by combining an additive ALE risk-scoring system using the coefficients of the significant predictive factors with the intraoperative water-sealing test.
RESULTS: In 485 consecutive thoracoscopic major pulmonary resections, ALE developed in 209 (43%) patients. Statistically significant ALE-associated preoperative factors included male sex, lower body mass index, radiologically evident emphysema, lobectomy, and upper lobe surgery. Significant ALE-associated intraoperative factors were incomplete fissure and pleural adhesion. The ALE risk scoring demonstrated an average area under the receiver operating characteristic curve of 0.72 in the fivefold cross-validation test. The ALE prediction algorithm correctly predicted ALE-absent patients at a negative predictive value of 80%.
CONCLUSIONS: The algorithm may promote the optimization of the chest tube-dwelling duration by identifying potential ALE-absent patients for accelerated tube removal.
Subject received standard-of-care radiotherapy or stereotactic body radiation therapy (SBRT) to one metastatic site. Manganese inhalation began 1 week after the start of radiotherapy and lasted up to 6 months. The same systemic therapy before the enrollment will be maintained.
The invention provides novel surface coat proteins of  Clostridium  spp. spores, and nucleic acids encoding such proteins. The invention extends to various uses of these nucleic acids and proteins, as antigens for use in vaccine design and construction, and to vaccines per se, and in diagnostic test kits and methods for the detection of  Clostridium  spp. infections. In addition, the nucleic acids and proteins can be used as potential targets for therapeutic drugs for the prevention or treatment of  Clostridium  spp. infections.
Background: It is the bladder, one of the organs with important functions in the urinary system. However, the bladder sometimes cannot work effectively as a result of neurological and sometimes non-neurological reasons. After this situation, urine in the bladder should be emptied. The bladder is one of the most frequently used organs in the urinary system. In neurogenic or non-neurogenic bladder disorders, the process of entering the bladder with a catheter in clean conditions, evacuating urine, and then removing the catheter is called Clean Intermittent Catheterization (CIC). CIC has been used by patients for nearly 40 years. CIC is one of the effective methods used to protect the urinary system, especially in children with Spina Bifida and people with urinary system problems. CIC application to children is done by caregivers. In the education of caregivers who have to apply CIC to their child the role of nurse to become more and more important. The aim of this study is to evaluate the effect of based on the roy adaptation theory supported android phone application CIC training, on the knowledge / skills, coping / adaptation and anxiety level of caregivers and the development of urinary tract infection in children.

Metod: The universe of the study consisted of the patients and their caregivers who were decided to perform CIC by Karadeniz Technical University Farabi Hospital Pediatric Nephrology Department. In order to determine the sample of the study, the test power in power analysis was calculated with the G \* Power 3.1 program. 95% confidence interval in determining the strength of the study; With 5% significance level and 0.50 effect size a total of 36 patients (df = 1; F = 4.130). 36 conforming patients were divided into experimental and control groups for a single- blind randomized control. The data will be collected using the introductory information form, the CIC application knowledge and skills form, based on North American Association of Nursing Diagnoses (NANDA) nursing diagnoses and Psychosocial Adaptation Area of Roy Adaptation Model form, Coping and Adaptation Scale and State Trait Anxiety Scale. In addition, for the diagnosis of urinary tract infection in participants undergoing CIC, urinalysis will be performed once a month, three times for three months. Patients with 100,000 colonies per milliliter of urine for urinalysis will be considered to have a urinary tract infection. No additional intervention will be made to caregivers in the control groups. Caregivers in the intervention group (Caregivers who will receive CIC training supported by Android phone application based on Roy adaptation model) will be given CIC training, home visit, and telephone conversation. In addition, an android phone application will be installed on the phones of the caregivers in the intervention group, which reminds the CIC times, procedure steps and hospital appointments. The data will be analyzed using SPSS versiyon with descriptive statistics, Independent t test and Anova in repeated measurements p\<0.05 will be statistically significant
The standard treatment regimen for esophageal cancer is chemoradiation followed by esophagectomy. However, the use of neoadjuvant chemoradiotherapy damages the surrounding tissue, which potentially increases the risk of postoperative complications, including anastomotic leakage. The impact of definitive chemoradiotherapy (dCRT, 50.4 Gy radiotherapy) compared to the standard neoadjuvant scheme (nCRT, 41.4 Gy radiotherapy) prior to surgery on the incidence of anastomotic leakage remains poorly understood. To study this, all patients who received dCRT between 2011 and 2021 followed by esophagectomy were included. For each patient, two patients who received nCRT were selected as matched controls. Outcomes included postoperative anastomotic leakage, pulmonary and other complications, anastomotic stenosis, pulmonary and other postoperative complications (Clavien Dindo Classification ≥1), and overall survival. One hundred and eight patients were included with a median follow-up of 28 months. The time between neoadjuvant treatment and surgery was longer in the dCRT group compared to the nCRT group (65 vs. 48 days, P < 0.001). Postoperatively, significantly more patients in the dCRT group suffered from anastomotic leakage (11% vs. 1%, P = 0.04) and anastomotic stenosis (42% vs. 17%, P < 0.01). No differences were found for other complications or overall survival between both groups. In conclusion, preoperative dCRT is associated with a higher risk of anastomotic leakage and stenosis. These complications, however, can be treated effectively. Therefore, esophagectomy after dCRT is considered to be an appropriate treatment strategy in a selected patient group.